Palisade Bio Reports Q3 GAAP EPS of -$0.07, Missing Estimates
Palisade Bio (PALI) has reported its third-quarter financial results, revealing a GAAP earnings per share (EPS) of -$0.07. This figure represents a $0.01 miss relative to analyst expectations. Despite the earnings miss, the company maintains a significant liquidity position, reporting $113.6 million in cash and cash equivalents as of September 30, 2024. The company continues its clinical focus, including upcoming studies related to its PDE4 inhibitor platform.
Tickers: $PALI
Topics: cash position EPS miss quarterly earnings